{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:37:50Z","timestamp":1792424270055,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360145"],"award-info":[{"award-number":["82360145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111718","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T19:41:01Z","timestamp":1708371661000},"page":"111718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-8595","authenticated-orcid":false,"given":"Peng","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111718_b0005","article-title":"The spectrum of biopsy-proven glomerular disease in china: a systematic review","volume":"131(6)","author":"Yang","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.intimp.2024.111718_b0010","doi-asserted-by":"crossref","unstructured":"2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases, Kidney Int100(4s): S1-s276.https:\/\/dx.doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"1","key":"10.1016\/j.intimp.2024.111718_b0015","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111718_b0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.111718_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.intimp.2024.111718_b0030","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2024.111718_b0035","article-title":"A new equation to estimate glomerular filtration rate","volume":"150(9)","author":"Levey","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.intimp.2024.111718_b0040","doi-asserted-by":"crossref","unstructured":"Seitz-Polski Barbara, Dahan Karine, Debiec Hanna, Rousseau Alexandra, Andreani Marine, Zaghrini Christelle, Ticchioni Michel, Rosenthal Alessandra, Benzaken Sylvia, Bernard Ghislaine, Lambeau G\u00e9rard, Ronco Pierre, Esnault Vincent L. M.\uff082019\uff09High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy, Clin J Am Soc Nephrol14(8): 1173-82.https:\/\/dx.doi.org\/10.2215\/CJN.11791018.","DOI":"10.2215\/CJN.11791018"},{"issue":"8","key":"10.1016\/j.intimp.2024.111718_b0045","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.intimp.2024.111718_b0050","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-021-04969-2","article-title":"Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed","volume":"41","author":"Daoussis","year":"2021","journal-title":"Rheumatol. Int."},{"issue":"3","key":"10.1016\/j.intimp.2024.111718_b0055","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-015-0859-6","article-title":"A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity","volume":"44","author":"Nulens","year":"2016","journal-title":"Infection"},{"issue":"10","key":"10.1016\/j.intimp.2024.111718_b0060","doi-asserted-by":"crossref","DOI":"10.18632\/aging.103344","article-title":"Why does COVID-19 disproportionately affect older people?","volume":"12","author":"Mueller","year":"2020","journal-title":"Aging"},{"issue":"2","key":"10.1016\/j.intimp.2024.111718_b0065","doi-asserted-by":"crossref","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatr. Nephrol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:14:49Z","timestamp":1761588889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924002364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":13,"alternative-id":["S1567576924002364"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111718","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111718"}}